Wendy L. Lin

Wendy L. Lin Research Analyst

B.S. from Yale University

Biography

Wendy joined Baron in 2022 as a research analyst and has 11 years of experience. Prior to joining Baron, she was a Health Care analyst at Goldman Sachs Asset Management. From 2016 to 2020, she was an associate analyst covering Health Care at Fred Alger Management. From 2013 to 2016 she was an equity research associate at J.P. Morgan Securities. Wendy graduated with distinction from Yale University with a B.S. in Applied Mathematics and Political Science in 2013.

Insights

  • A Multi-Billion-Dollar Drug Market

    April 15, 2024 -

    In the latest Baron Insights, our investment team does a deep dive into a new class of weight loss drugs and why they have the potential to be the largest drug class in the history of health care.

  • Baron Capital Thought Leadership Forum | January 2024

    The latest Baron Capital Thought Leadership Forum looks at how GLP-1s work, their transformative impact on the medical approach to weight loss, and the implications for growth companies leading in the production of GLP-1 drugs.